We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Superior Enzymes Invited to Talk at 31st Annual National Environmental Monitoring Conference

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Superior Enzymes will be an invited speaker at the 31st Annual National Environmental Monitoring Conference in Chicago, Illinois on Thursday, July 14th.  This is the second consecutive year our organization has received the honor of presenting to our colleagues in this forum.  

When we started working in the new field of genetic engineering 30 years ago, it was a struggle to explain our work to friends and family. Now people make jokes about DNA. Our struggle continued as we tried to explain what enzymes are. For the first years of NECi, chemists balked at the idea of enzymes for water testing. The inherent dangers and toxicity exposures of a chemistry lab were taken for granted – ever check out life insurance rates for chemists? Sensitivity to parts per million for many analytes was a great achievement of the second half of the 20th century, now detection limits down to single molecules is in the news these days. It’s been clear that there’s always room for the next improvement in the lab.

But change is always hard. Displacing the tried-and-true is harder than adopting something never done before. And that’s where we have seen the obstacles to adoption of enzyme-based analytical chemistry outside the biomedical or clinical lab. Advantages in selectivity (simplifying sample prep), sensitivity, and safety are finally gaining attention from the lab community. These trends are aiding NECi in recruiting a variety of stakeholders in collaborative efforts at new method validation.

Ellen will share her experiences in both the technology and method development, but also the marketing and implementation of the methods in the labs.  She will recount regulatory hurdles and the pitfalls of evolving from the lunatic fringe, to state of the art.